Clinical Trial Update: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) [Phase 3]

View source ↗

Summary

GeparOcto is a Phase III neoadjuvant trial comparing two dose-dense, dose-intensified regimens for high-risk early breast cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III | Phase 3 | Status: COMPLETED